Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeted Protein Degradation (TPD) and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CUL3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CUL3 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for in vitro E3 ligase reconstitution. |
View CUL3 Products |
| Gene Delivery | CUL3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and E3 ligase overexpression assays. |
View CUL3 Products |
| Benchmark Ab | Anti-CUL3 Recombinant Antibody High-specificity recombinant positive control for Western Blot, IP, and ELISA assays. |
View CUL3 Products |
| Validator | CUL3 siRNA Set For target knockdown verification and specificity profiling in phenotypic assays. |
View CUL3 Products |
| Related Target A | KEAP1 The primary BTB-domain adaptor protein recruiting Nrf2 to the CUL3 ubiquitin ligase complex. |
View KEAP1 Products |
| Related Target B | RBX1 The RING-finger protein that binds CUL3 to recruit the ubiquitin-conjugating enzyme (E2). |
View RBX1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting Active multi-protein E3 complexes | Sequence-verified, highly stable recombinant CUL3 and partner proteins (RBX1, KEAP1) with optimized tags for pull-down and TR-FRET. |
| Assaying intracellular degradation kinetics | Lentivirus premade particles for robust, stable expression of CUL3 wild-type or disease-associated mutants in target cell lines. |
| Lack of Controls | Sequence-defined recombinant benchmark antibodies included for consistent assay baselines. |
| False Positives | Validated siRNA sets included for target-specific knockdown to confirm mechanism of action. |
Live CUL3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CUL3 therapeutics is intensifying, with major players shifting focus from traditional small-molecule inhibitors to Targeted Protein Degradation (TPD), including PROTACs and molecular glues. As first-generation E3 ligase recruiters (targeting CRBN and VHL) face clinical resistance and tissue-limitation challenges, the next wave of R&D is targeting alternative E3 ligases like the CUL3-BTB complex. CUL3-based degraders leverage specific BTB adaptor proteins (such as KEAP1 or SPOP) to achieve tissue-selective protein degradation, particularly in solid tumors and inflammatory pathways where Nrf2/KEAP1 signaling is dysregulated.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glues / PROTACs | Arvinas, Kymera Therapeutics, Monte Rosa Therapeutics | Solid Tumors (NSCLC, Breast Cancer), Autoimmune Diseases | Ternary Complex Formation Assay (Requires high-purity CUL3 and adaptor proteins) |
| Small Molecule Inhibitors (KEAP1-CUL3) | AstraZeneca, Boehringer Ingelheim | Nrf2-activated Cancers, Chronic Kidney Disease (CKD) | Disruption Assay (Requires robust recombinant KEAP1/CUL3 binding partners) |
| Gene Therapy / Knockdown | Academic Institutes, Biotech Startups | Pseudohypoaldosteronism Type II (PHA2E), Hypertension | Target Validation (Requires sequence-verified CUL3 siRNA and Lentivirus) |